Aikejia |
|
Vaxjo ID |
404 |
|
Vaccine Adjuvant Name |
Aikejia |
|
Alternative Names |
Aikejia may be referred to as Nocardia rubra cell-wall skeleton (N-CWS). |
|
Adjuvant VO ID |
VO_0005686
|
|
Description |
Aikejia is an immunomodulatory drug derived from the cell wall of Nocardia rubra. It is known to enhance the immune response by increasing the levels of inflammatory cytokines and activating various immune cells. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
Aikejia comes from Nocardia rubra cell-wall skeleton and can increase the number of inflammatory factors and immune cells |
|
Preparation |
Aikejia is prepared through a series of chemical extraction and refining processes from Nocardia rubra. |
|
Dosage |
In the study, Aikejia was administered at doses of 0.5 ug, 1 ug, or 2 ug per mouse. |
|
Function |
Our results suggested that Aikejia may be an effective adjuvant for PD-1/PD-L1 immunotherapy. |
|
Safety |
The article indicates that Aikejia has been used clinically for many years and has a high safety profile, showing controllability and minimal adverse effects. |
| References |
Huang et al., 2019: Huang C, Tang X, Li S, Wang Q, Xie B, Xu J, Lin Y. Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell. Journal of Cancer. 2019; 10(15); 3472-3480. [PubMed: 31293651].
|
